aTyr Pharma (NASDAQ:ATYR – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.15) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 12:30 PM ET.
aTyr Pharma (NASDAQ:ATYR – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. On average, analysts expect aTyr Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
aTyr Pharma Stock Up 7.6%
Shares of NASDAQ:ATYR opened at $0.53 on Wednesday. The company has a 50-day moving average price of $0.51 and a two-hundred day moving average price of $0.71. aTyr Pharma has a twelve month low of $0.40 and a twelve month high of $6.50. The firm has a market capitalization of $51.89 million, a PE ratio of -0.72 and a beta of 0.54.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on ATYR
Insider Activity
In other aTyr Pharma news, Director Paul Schimmel acquired 100,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was bought at an average price of $0.50 per share, with a total value of $50,000.00. Following the completion of the purchase, the director owned 779,143 shares of the company’s stock, valued at approximately $389,571.50. This represents a 14.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 5.75% of the company’s stock.
Institutional Trading of aTyr Pharma
A number of large investors have recently modified their holdings of ATYR. Vanguard Group Inc. grew its holdings in shares of aTyr Pharma by 21.0% during the third quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company’s stock worth $4,060,000 after purchasing an additional 975,887 shares in the last quarter. UBS Group AG raised its stake in aTyr Pharma by 158.1% in the third quarter. UBS Group AG now owns 4,505,955 shares of the company’s stock valued at $3,249,000 after purchasing an additional 2,760,238 shares in the last quarter. Octagon Capital Advisors LP lifted its position in aTyr Pharma by 7.5% during the second quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company’s stock valued at $19,367,000 after purchasing an additional 268,000 shares during the last quarter. Geode Capital Management LLC lifted its position in aTyr Pharma by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company’s stock valued at $1,789,000 after purchasing an additional 105,514 shares during the last quarter. Finally, Millennium Management LLC grew its stake in aTyr Pharma by 22.0% in the 3rd quarter. Millennium Management LLC now owns 1,890,921 shares of the company’s stock worth $1,364,000 after buying an additional 340,721 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.
The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.
Read More
- Five stocks we like better than aTyr Pharma
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
